Johnson & Johnson: Kidney Failure, Chronic trials

The registry lists 11 Kidney Failure, Chronic studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 3Phase 2 3Phase 3 2Phase 4 2No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.CompletedNCT00337935Phase 2Results posted
• A Study of Orally Administered Pimodivir in Adult Participants With Renal ImpairmentTerminatedNCT03947814Phase 1
• A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal FunctionCompletedNCT03546205Phase 1
• An Efficacy, Safety, Tolerability and Pharmacokinetics Study of 12 Weeks Treatment With Simeprevir and Daclatasvir in Participants With Chronic Hepatitis C Virus Genotype 1b or 4 Infection and Either Severe Renal Impairment or End-stage Renal Disease on Hemodialysis.WithdrawnNCT02397395Phase 2
• A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance HemodialysisCompletedNCT02289703Phase 1
• New Needle for Two-Needle HemodialysisStatus unknownNCT01416896Phase 2/3
• Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney FailureCompletedNCT00391287
• EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal FailureCompletedNCT00338000Phase 4
• Effects of Early Correction of Anemia in Patients With Chronic Renal InsufficiencyTerminatedNCT00312871Phase 4
• A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis PatientsCompletedNCT00261521Phase 3
• Study to Monitor the Incidence of Pure Red Cell Aplasia (PRCA) and/or Antibodies to Erythropoietin Among Participants Receiving Epoetin Alfa or Another ErythropoietinCompletedNCT00210951